Skip to main navigation

Header Nav

Company
Pipeline and Technology
Business Development
Investors
Contact Us

Select Page

Press Releases

Header Nav

Welcome
Financial Information
Financial Fundamentals
Stock Information
- Stock Quote & Chart
- Historic Price Lookup
Filings
- SEC Filings
- Ownership
Corporate Governance
Corporate Presentation
Events
Press Releases
Investor Alerts

Toolkit

Email Alerts
Print Page
Share
RSS Feeds
Contact IR
Search

Press Releases

Year

Mar 13, 2023

Windtree Regains Compliance with Nasdaq

WARRINGTON, Pa. , March 13, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced it has received a Bid Price Compliance Letter from The

Mar 6, 2023

Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime

US Hospital Claims Data Reveals Cardiogenic Shock Patients Have an Average Hospital Length of Stay of 19.6 Days Making Its Intensive Patient Care Cost Very High WARRINGTON, Pa. , March 06, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a

Feb 28, 2023

Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure

Additionally, the USPTO Has Published the Patent Application for One Group of Windtree’s SERCA2a Activators WARRINGTON, Pa. , Feb. 28, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple

Feb 27, 2023

Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference

WARRINGTON, Pa. , Feb. 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, is targeting cardiogenic shock as a potential indication for its drug

Feb 24, 2023

Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office

New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039 WARRINGTON, Pa. , Feb. 24, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple

Feb 23, 2023

Windtree Therapeutics Announces Reverse Stock Split

WARRINGTON, Pa. , Feb. 23, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the Company’s Board of Directors has

Jan 20, 2023

Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants

WARRINGTON, Pa. , Jan. 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”) today announced it has entered into warrant inducement offer letters (the “Inducement Offer Letters”) to raise approximately $1.0 million in gross proceeds from the exercise

YM Twitter Feed